6. The authors should clarify aspects of specimen handling. Will biosamples be frozen at each participating centre prior to transportation to a central laboratory or will they be frozen only after transport?
7. The authors should explain why they chose 40% decline in GFR to define decline in kidney function, since this is not a standard definition.
8. The authors should provide some additional detail on how outcomes will be ascertained eg from medical records, national databases or death certificates etc.
9. Participants will be recruited from multiple sites. What measures have been taken to ensure to minimize variation in the assessments between sites?
10. The authors have demonstrated that they are likely to have adequate statistical power for multivariable analysis of determinants of mortality in this population. However, published studies suggest that the incidence of ESRD is likely to be very low and the study may therefore not be adequately powered to analyse determinants of ESRD 14. There are minor weaknesses in the language in places.
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GENERAL COMMENTS
Author reported a project for important topic concerning elderly. There is methodology limitation. Author's don't explain the method of inclusion to discuss transportability in the country and elsewhere and there is a lot of exclusion criteria. The age selection is low (i.e 65yrs) to study elderly population. Authors don't precise if they plan an association or prognosis study according to consort checklist. Authors defined a secondary outcome such as peripheral vascular disease without definition. To conclude an interesting project which need methodoly improvment. 2. In the abstract it should be clarified that the secondary endpoints are hospitalization for each of the conditions listed. Response: We have clarified that the secondary endpoints are hospitalization for acute coronary syndrome, heart failure, cerebral stroke, and peripheral arterial disease in the abstract.
VERSION 1 -AUTHOR RESPONSE
3. The authors should clarify whether a diagnosis of CKD will require to eGFR values <60ml/min/1.73m2 as required by the KDIGO definition or just a single value as is often done in pragmatic epidemiological studies. Response: We defined CKD as glomerular filtration rate (GFR) less than 60 ml/min/1.73m2 and/or proteinuria based on one measurement, which is common used in pragmatic epidemiological studies. But for patients with suspected acute kidney injury (AKI), we did measured GFR several times with intervals and made sure to exclude patients with AKI. We have clarified this in the manuscript.
4. The authors should explain why 2 different equations, MDRD and CKD-EPI, will be used to estimate GFR and what steps have been taken to ensure that results from different centres are comparable.
Response: In recent years Roche enzymatic method is common used when measuring serum creatinine, but some hospitals still adopt the Jaffe's kinetic method. The original literatures from which we quoted two equations detailed the method of serum creatinine measurement. The MDRD equation was induced based on Scr that tested by Jaffe's kinetic method, and CKD-EPI equation was induced based on Scr that measured by Roche enzymatic method.
5. Item 8 under the exclusion criteria is unclear. It states cognitive impairment but then mentions the New York Heart Association classification for heart failure. Response: Sorry for the mistake. Item 8 under the exclusion criteria is heart failure. The statement has been revised in the manuscript.
6. The authors should clarify aspects of specimen handling. Will biosamples be frozen at each participating centre prior to transportation to a central laboratory or will they be frozen only after transport? Response: After simple processing, the samples will be frozen at -80 at each clinic center, and then transported to the central laboratory by cold-chain every three months for future use. And we have clarified it in the manuscript.
7. The authors should explain why they chose 40% decline in GFR to define decline in kidney function, since this is not a standard definition. Response: Doubling of serum creatinine or 50% decline in GFR has been wildly adopted in clinical trials as an endpoint for CKD progression. However, regarding lesser eGFR decline as an alternative endpoint for CKD progression has the potential to reduce costs, shorten follow-up duration, and thus increase efficiency of clinical trials. It is reported that declines in eGFR less than doubling of serum creatinine occur more commonly and are strongly and consistently associated with the risk of ESRD and mortality, supporting consideration of lesser declines in eGFR, such as 30% reduction over 2 years, as an alternative endpoint for CKD progression . Several other studies also support a 30% to 40% decline in eGFR as an outcome for clinical trials in CKD , , . Thus, we chose 40% decline in GFR as an endpoint of CKD progression.
8. The authors should provide some additional detail on how outcomes will be ascertained eg from medical records, national databases or death certificates etc. Response: First, participants are asked to return for in-person follow-up visits. Clinical centers will query about possible study outcomes and update the contact information. Suspected end-point events will be ascertained by an independent end-point assessment committee organized by Chinese PLA General Hospital. Secondly, an electronic database was established, through which the Chinese PLA General Hospital could supervise periodically for all participants to ensure complete information entering and occurrence of outcome events. Third, ascertainment of outcomes was supplemented by reports by patient proxies, hospital medical records and death certificates. We have detailed it in the manuscript.
9. Participants will be recruited from multiple sites. What measures have been taken to ensure to minimize variation in the assessments between sites? Response: A series of measures were included to minimize potential variation in the assessments between sites: (1) The staff of each study center who will participate in C-OPTION were trained before the start of study; (2) We have drawn up a manual of procedure (MOP) and distributed it to each investigator. The detailed instructions of aspects of the study were displayed in a uniform and standard manner; (3) An electronic database was established, and each site was asked to put the data into the database in time; (4) A professional academic research organization composed of senior nephrologists, biostatisticians and epidemiologist was responsible for supervising the quality of data. Every month about 5-10% of the cases from each participating site was selected randomly, and the validity of the data and questionnaires were checked. The unqualified data were sent back to the investigators and recollected or refilled. Repeated training to investigators will be done if necessary.
10. The authors have demonstrated that they are likely to have adequate statistical power for multivariable analysis of determinants of mortality in this population. However, published studies suggest that the incidence of ESRD is likely to be very low and the study may therefore not be adequately powered to analyse determinants of ESRD (Shardlow A et al. in Southwest, to ensure data from a broad range of participants. The detailed geographical partitions can be seen from http://en.wikipedia.org/wiki/List_of_regions_of_the_People%27s_Republic_of_China. Given the convenience for survey, we included patients from hospitals instead of communities. This may limit our ability to provide data representative of all elderly population. But this will still be the largest and in-depth national survey of elder patients with CKD across China.
12. The authors should remove their claim in the conclusion that this is the first prospective cohort study to study CKD in older patients. 13. The authors should add a brief section discussing the limitations of their study. Response: We have added this section to the manuscript. This study has some limitations. First, we recruited subjects based on a single measure of Scr and/or albuminuria without 3 months interval. And there is no uniform and perfect eGFR equation to evaluate kidney function in elderly population. Second, there may be potential selection bias or confounder effects. This study cohort was from tertiary hospitals instead of communities. And we excluded participants with severe impaired functional function that unable to complete the study procedure even if assisted. So the generalizability of the results to other populations remains to be confirmed. Finally, the observational design precludes causality.
14. There are minor weaknesses in the language in places.
Response：Language presentation was improved with assistance from a native English speaker with appropriate research background. Author reported a project for important topic concerning elderly.
-There is methodology limitation. Authors don't explain the method of inclusion to discuss transportability in the country and elsewhere and there is a lot of exclusion criteria. Response: First, the inclusion criteria are standard. Before the start of this study, we made a survey and realized that either albumin excretion rate (AER) or albumin-to-creatinine ratio (ACR) measurement can be carried out in the participating centers. In addition, Chinese PLA General Hospital hosts the central bio-bank and the central laboratories. Bio-samples will be collected in each participating site, stored at −80°C and transported to the central laboratory by cold-chain. As for the exclusion criteria, the subjects in question are patients with CKD, so we excluded those with AKI. Because isolated hematuria is just a sign of suspected kidney injury but not enough to a CKD diagnosis, we excluded those with isolated hematuria. We aim to find factors of the adverse outcomes (including death, ESRD, cardiovascular events), so we excluded patients who already had ESRD, and who have limited life expectancy because of severe comorbidity such as active tumor. What's more, there are questionnaires and surveys to be done, thus we excluded patients who were unable to communicate with examiners or complete the study procedure.
-The age selection is low (i.e 65yrs) to study elderly population. Response: Thanks for your kind suggestion. Although most developed countries accept the chronological age of 65 years as a definition of 'elderly' person, there is no standard numerical criterion. And studies among elderly patients with kidney injury adopt different cut-offs, ranging from 55-80 years old and even older. It is known that renal structure changes and renal function decreases with age. National Health and Nutrition Examination Survey (NHANES) showed that the prevalence of CKD is 38% in participants over 65 years of age compared with 13% in the overall US population . What's more, age-related comorbidities and geriatric syndromes can occur in patients older than 60 or 65 years old. Given this, we adopted 65yrs as a cut-off to enroll subjects, and if necessary, subgroup analysis (i.e 65-70yrs, 70-80yrs, ≥80yrs) could be done.
-Authors don't precise if they plan an association or prognosis study according to consort checklist. Response: We designed this cohort study according to STROBE Checklist since it is an observational study without intervention, not a randomized controlled trial.
-Authors defined a secondary outcome such as peripheral vascular disease without definition. Response: Second endpoints include: (1) acute myocardial infarction; (2) hospitalization for congestive heart failure; (3) hospitalization for unstable angina；(4) cerebrovascular events including intracranial hemorrhage, subarachnoid hemorrhage, ischemic stroke; and (5) peripheral arterial disease. Acute myocardial infarction is defined as elevated levels of cardiac enzymes accompanied by symptoms such as a sudden painful sensation of pressure in the chest, profuse perspiration, nausea and vomiting, ECG changes compatible with ischemia or infarction , or new fixed perfusion abnormalities with corroborating wall motion. Congestive heart failure is defined as hospitalization for new or abrupt worsening of signs and symptoms combined with falling cardiac output. Unstable angina is defined as more than 10 minutes of ischemic symptoms that can not be relieved by nitrate drugs (resting pain, shortness of breath, squeezing or discomfort), combined with new or aggravated ECG changes or imaging evidence of myocardial ischemia, without changes of myocardial necrosis markers.
